Protection against symptomatic SARS-CoV-2 BA.5 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original (ancestral) monovalent vaccines – a matched cohort study in France

Vincent Auvigne, Cynthia Tamandjou, Justine Schaeffer, Sophie Vaux, Isabelle Parent du Chatelet
doi: https://doi.org/10.1101/2023.03.17.23287411
Back to top
Posted March 18, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Protection against symptomatic SARS-CoV-2 BA.5 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original (ancestral) monovalent vaccines – a matched cohort study in France
Vincent Auvigne, Cynthia Tamandjou, Justine Schaeffer, Sophie Vaux, Isabelle Parent du Chatelet
medRxiv 2023.03.17.23287411; doi: https://doi.org/10.1101/2023.03.17.23287411
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area